Previous 10 | Next 10 |
Finalizing preparations for pharmacokinetic (PK) clinical trials of AQST-108 First planned PK clinical trial expected to begin during the third quarter of 2020 WARREN, N.J., Aug. 10, 2020 (GLOBE NEWSWIRE) -- Aquestive Therapeutics, Inc. (NASDAQ: AQST), a pharmaceutical company focused...
Image source: The Motley Fool. Aquestive Therapeutics, Inc. (NASDAQ: AQST) Q2 2020 Earnings Call Aug 05, 2020 , 8:00 a.m. ET Operator Continue reading
For Q2 , Aquestive Therapeutics ( AQST +6.2% ) revenues of $21.7M vs. $11.1M; indicating increased licensing fees and royalty revenue ($12M for KYNMOBI approval). More news on: Aquestive Therapeutics, Inc., Earnings news and commentary, Stocks on the move, Healthcare stocks news,...
Aquestive Therapeutics, Inc. (AQST) Q2 2020 Results Earnings Conference Call August 5, 2020, 08:00 AM ET Company Participants Stephanie Carrington - Westwicke, Investor Relations Keith Kendall - President and Chief Executive Officer John Maxwell - Senior Vice President and Chief ...
Aquestive Therapeutics (NASDAQ: AQST ) : Q2 GAAP EPS of -$0.07 beats by $0.36 . More news on: Aquestive Therapeutics, Inc., Earnings news and commentary, Healthcare stocks news, , Read more ...
Generated 59% year-over-year revenue growth for Sympazan ® (clobazam) FDA completed safety review of IND for AQST-108 (epinephrine) and approved commencement of first planned pharmacokinetics (PK) clinical trials Continues to advance Libervant™ (diazepam...
WARREN, N.J., July 28, 2020 (GLOBE NEWSWIRE) -- Aquestive Therapeutics, Inc. (NASDAQ:AQST), a pharmaceutical company focused on developing and commercializing differentiated products that address patients’ unmet needs and solve therapeutic problems, today announced that management wi...
WARREN, N.J., July 15, 2020 (GLOBE NEWSWIRE) -- Aquestive Therapeutics, Inc. (NASDAQ: AQST), a pharmaceutical company focused on developing and commercializing differentiated products that address patients’ unmet needs and solve therapeutic problems, announced today that it will repo...
Aquestive Therapeutics (NASDAQ: AQST ) has submitted an IND application to the FDA for pharmacokinetic (PK) clinical trials of AQST-108, an oral sublingual film formulation delivering systemic epinephrine in development for the treatment of anaphylaxis (serious allergic reaction). M...
Expects to initiate its planned pharmacokinetic (PK) clinical trials before year end 2020 This program will be reviewed under the 505(b)(2) regulatory approval pathway AQST-108 may address an unmet need in patients requiring rescue medication for anaphylaxis WARREN, N.J., June 29, 20...
News, Short Squeeze, Breakout and More Instantly...
Aquestive Therapeutics Inc. Company Name:
AQST Stock Symbol:
NASDAQ Market:
Aquestive Therapeutics Inc. Website:
Late-stage pipeline program, Anaphylm™ (epinephrine) Sublingual Film, remains on track for a near-term New Drug Application (NDA) submission to the FDA Expanded sales coverage for Libervant™ (diazepam) Buccal Film for patients between ages two to five with national retail distri...
Clearwater Paper Corporation (CLW) is expected to report for Q2 2024 Amgen Inc. (AMGN) is expected to report $4.93 for Q2 2024 Bain Capital Specialty Finance Inc. (BCSF) is expected to report $0.47 for Q2 2024 Axon Enterprise Inc. (AXON) is expected to report $0.55 for Q2 2024 Ame...
Meets primary study endpoints with pharmacokinetics (PK) comparable whether Anaphylm is administered by subjects or by healthcare providers (HCPs) Final supportive study, the Oral Allergy Syndrome (OAS) challenge study, currently enrolling Continues to anticipate requesting a pr...